DPFS is an ongoing scheme, with outline deadlines every 4 months.
Further details of open and future DPFS deadlines can be found on the submission deadlines page for the scheme.
The DPFS scheme is a key part of our Translational Research Strategy and supports the translation of fundamental discoveries toward benefits to human health. It funds the pre-clinical development and early clinical testing of novel therapeutics, devices and diagnostics, including “repurposing” of existing therapies.
The Canadian agencies and UKRI are pleased to announce their intention to launch the Canada-UK Artificial Intelligence Initiative. Up to £8 million (CAN $14 million) is available, enough to fund 10 projects between the UK and Canada.
The Medical Research Council (MRC), the UK Economic and Social Research Council (ESRC) and the Canadian Institutes of Health Research (CIHR) are pleased to invite proposals to the UK-Canada Diabetes Partnership Initiative.
The Japan Agency for Medical Research and Development (AMED) and the UK Medical Research Council (UKRI MRC) are pleased to launch a call for proposals for UK-Japan collaborative research into infectious diseases. This jointly funded initiative is aimed at fostering collaborative links between researchers in the UK and Japan.
You can apply to the Molecular & Cellular Medicine Board through four of our grant schemes.
The UK MRC and South African MRC (SAMRC) are pleased to invite proposals to the South Africa – UK Antibiotic Accelerator under the umbrella of the Newton Fund.
This initiative will provide funding for high quality collaborative research partnerships focused on addressing the growing global burden of antimicrobial resistance, specifically antibacterial resistance in (South) Africa, through drug discovery.
This joint BBSRC, EPSRC and MRC 2019 Tools and Resources Development Fund (TRDF) call aims to pump prime the next generation of cutting-edge enabling research technologies with the potential for transformative impact in life sciences research.
You can apply to the Infections and Immunity Board through our four grant schemes.